UCB Licenses Sepracor U.S. patents for antihistamine Levocetirizine

27-Feb-2006

UCB S.A. and Sepracor Inc. announced a licensing agreement relating to the antihistamine levocetirizine. Under this agreement, Sepracor has exclusively licensed to UCB all of Sepracor's patents and patent applications in the United States regarding levocetirizine and royalties will be payable to Sepracor on U.S. sales of levocetirizine products.

Under a separate agreement, Sepracor currently earns royalties from UCB on sales of levocetirizine in European countries where the product is sold. Levocetirizine is marketed by UCB under the brand names XYZAL® and XUSALT in the European Union for treatment of symptoms of seasonal and perennial allergic rhinitis, persistent allergic rhinitis, and chronic idiopathic urticaria (CIU, also known as hives of unknown cause) in adults and children aged 6 years and older.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...